Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weijing Sun

Showing results (111-120 of 139) with videos related to

Pageof 14
Sort By:
Cancer|January 26, 2011
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinomaWeijing Sun, Davendra Sohal, Daniel G Haller, et al.
The American Journal of Surgical Pathology|January 31, 2015
Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survivalAatur D Singhi, Tyler J Foxwell, Katie Nason, et al.
American Journal of Clinical Oncology|April 24, 2014
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II studyHoward Safran, Thomas Miner, Nathan Bahary, et al.
Nature Communications|April 12, 2025
Gut commensal Bifidobacterium-derived extracellular vesicles modulate the therapeutic effects of anti-PD-1 in lung cancerRanjan Preet, Md Atiqul Islam, Jiyoung Shim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flowJames P Stevenson, Mark Rosen, Weijing Sun, et al.
JAMA Oncology|July 19, 2019
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical TrialEileen M O'Reilly, Do-Youn Oh, Neesha Dhani, et al.
Cancer Medicine|June 16, 2023
A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinomaWeijing Sun, Nirmal Veeramachaneni, Raed Al-Rajabi, et al.
Science (New York, N.Y.)|March 26, 2011
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humansGregory L Beatty, Elena G Chiorean, Matthew P Fishman, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2013
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancerDavendra P S Sohal, James M Metz, Weijing Sun, et al.
Cell Reports. Medicine|January 26, 2023
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial resultsAnwaar Saeed, Robin Park, Junqiang Dai, et al.
Pageof 14

Showing results (111-120 of 139) with videos related to

Sort By:
Pageof 14
Cancer|January 26, 2011
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinomaWeijing Sun, Davendra Sohal, Daniel G Haller, et al.
The American Journal of Surgical Pathology|January 31, 2015
Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survivalAatur D Singhi, Tyler J Foxwell, Katie Nason, et al.
American Journal of Clinical Oncology|April 24, 2014
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II studyHoward Safran, Thomas Miner, Nathan Bahary, et al.
Nature Communications|April 12, 2025
Gut commensal Bifidobacterium-derived extracellular vesicles modulate the therapeutic effects of anti-PD-1 in lung cancerRanjan Preet, Md Atiqul Islam, Jiyoung Shim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flowJames P Stevenson, Mark Rosen, Weijing Sun, et al.
JAMA Oncology|July 19, 2019
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical TrialEileen M O'Reilly, Do-Youn Oh, Neesha Dhani, et al.
Cancer Medicine|June 16, 2023
A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinomaWeijing Sun, Nirmal Veeramachaneni, Raed Al-Rajabi, et al.
Science (New York, N.Y.)|March 26, 2011
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humansGregory L Beatty, Elena G Chiorean, Matthew P Fishman, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2013
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancerDavendra P S Sohal, James M Metz, Weijing Sun, et al.
Cell Reports. Medicine|January 26, 2023
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial resultsAnwaar Saeed, Robin Park, Junqiang Dai, et al.
Pageof 14